DE69718924D1 - Fusogene liposomzusammensetzung und verfahren - Google Patents

Fusogene liposomzusammensetzung und verfahren

Info

Publication number
DE69718924D1
DE69718924D1 DE69718924T DE69718924T DE69718924D1 DE 69718924 D1 DE69718924 D1 DE 69718924D1 DE 69718924 T DE69718924 T DE 69718924T DE 69718924 T DE69718924 T DE 69718924T DE 69718924 D1 DE69718924 D1 DE 69718924D1
Authority
DE
Germany
Prior art keywords
liposome
composition
target cells
hydrophobic polymers
liposome composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69718924T
Other languages
English (en)
Other versions
DE69718924T2 (de
Inventor
J Martin
Samuel Zalipsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Sequus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequus Pharmaceuticals Inc filed Critical Sequus Pharmaceuticals Inc
Publication of DE69718924D1 publication Critical patent/DE69718924D1/de
Application granted granted Critical
Publication of DE69718924T2 publication Critical patent/DE69718924T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
DE69718924T 1996-10-11 1997-10-10 Fusogene liposomzusammensetzung und verfahren Expired - Fee Related DE69718924T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2826996P 1996-10-11 1996-10-11
PCT/US1997/018838 WO1998016202A2 (en) 1996-10-11 1997-10-10 Fusogenic liposome composition and method

Publications (2)

Publication Number Publication Date
DE69718924D1 true DE69718924D1 (de) 2003-03-13
DE69718924T2 DE69718924T2 (de) 2003-12-04

Family

ID=21842486

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69718924T Expired - Fee Related DE69718924T2 (de) 1996-10-11 1997-10-10 Fusogene liposomzusammensetzung und verfahren

Country Status (15)

Country Link
US (1) US5891468A (de)
EP (1) EP0932391B1 (de)
JP (1) JP2001504093A (de)
AT (1) ATE232086T1 (de)
AU (1) AU715063B2 (de)
BR (1) BR9712230A (de)
CA (1) CA2267904C (de)
DE (1) DE69718924T2 (de)
DK (1) DK0932391T3 (de)
ES (1) ES2191833T3 (de)
HK (1) HK1047550A1 (de)
IL (1) IL129292A0 (de)
PT (1) PT932391E (de)
TW (1) TW520297B (de)
WO (1) WO1998016202A2 (de)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US20070036722A1 (en) * 1996-10-28 2007-02-15 Pal Rongved Separation processes
CA2271325A1 (en) * 1996-11-12 1998-05-22 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
US6372720B1 (en) 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
US6936729B2 (en) * 1998-05-16 2005-08-30 Mirus Bio Corporation Compound containing a labile disulfide bond
US7087770B2 (en) 1998-05-16 2006-08-08 Mirus Bio Corporation Compound containing a labile disulfide bond
CA2346879A1 (en) 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
DE69938148T2 (de) * 1998-12-18 2009-02-26 Alza Corp., Mountain View Verfahren zur verabreichung von einer verbindung an mehrfachresistente zellen
US6379698B1 (en) * 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
EP1173600A2 (de) * 1999-04-20 2002-01-23 The University Of British Columbia Kationische peg-lipide und verfahren zu ihrer verwendung
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
CN100512879C (zh) * 1999-04-23 2009-07-15 阿尔萨公司 用于脂质体中的有可裂解键的缀合物
WO2000064483A2 (en) * 1999-04-23 2000-11-02 Alza Corporation Releasable linkage and compositions containing same
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
AUPQ014699A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
AU5395000A (en) * 1999-05-27 2000-12-18 Zeptosens Ag Vesicle containing polymers and sensor detection methods based thereon
CA2379060A1 (en) * 1999-07-14 2001-01-25 Alza Corporation Neutral lipopolymer and liposomal compositions containing same
WO2001026625A2 (en) 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery
US20040197390A1 (en) * 2001-05-29 2004-10-07 Shi-Kun Huang Neutral-cationic lipid for systemic delivery of factor VIII gene
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6916488B1 (en) * 1999-11-05 2005-07-12 Biocure, Inc. Amphiphilic polymeric vesicles
ATE419833T1 (de) * 1999-11-24 2009-01-15 Transave Inc Modulares zielgerichtetes liposomales verabreichungssytem
AU2136501A (en) * 1999-12-10 2001-06-18 Celator Technologies Inc. Lipid carrier compositions with protected surface reactive functions
DK1274399T3 (da) * 2000-01-28 2005-08-08 Alza Corp Liposomer indeholdende en indesluttet forbindelse i overmættet oplösning
WO2001080900A2 (en) * 2000-04-20 2001-11-01 The University Of British Columbia Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
PL212211B1 (pl) * 2000-06-02 2012-08-31 Regents Board Of Kompozycja do wytwarzania scyntygraficznego środka obrazującego, kompozycja do obrazowania scyntograficznego, sposób syntezy znakowanego radionuklidem koniugatu etylenodicysteiny z ligandem naprowadzającym do obrazowania, zastosowanie kompozycji zawierającej znakowany radionklidem konigat etylenodiscysteiny z ligandem naprowadzającym do wytwarzania środków farmaceutycznych do obrazowania nowotworu albo miejsca infekcji oraz zestaw do wytwarzania preparatów radiofarmaceutycznych
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
WO2002036073A2 (en) * 2000-11-02 2002-05-10 Smithkline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
US6613280B2 (en) 2001-03-20 2003-09-02 Therox, Inc. Disposable cartridge for producing gas-enriched fluids
WO2002076394A2 (en) * 2001-03-22 2002-10-03 The Ohio State University Research Foundation Enzyme-based anti-cancer compositions and methods
IL158160A0 (en) * 2001-03-26 2004-03-28 Alza Corp Liposome composition for improved intracellular delivery of a therapeutic agent
EP1383480A4 (de) * 2001-04-30 2006-05-24 Targeted Genetics Corp Lipidenthaltende arzneimittelabgabe-komplexe und herstellungsverfahren dafür
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
JP4358521B2 (ja) * 2001-05-18 2009-11-04 サーナ・セラピューティクス・インコーポレイテッド 細胞デリバリーのためのコンジュゲートおよび組成物
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050158735A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US8216585B2 (en) 2001-05-25 2012-07-10 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
IL161733A0 (en) 2001-11-02 2005-11-20 Insert Therapeutics Inc Methods and compositions for therapeutic use of rna interference
GB0129121D0 (en) * 2001-12-05 2002-01-23 Ic Vec Ltd Compound
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2503094A1 (en) * 2002-02-27 2003-09-04 The Ohio State University Research Foundation Therapeutic methods for acute myeloid leukemia
US7018655B2 (en) * 2002-03-18 2006-03-28 Labopharm, Inc. Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions
WO2003083443A2 (en) * 2002-03-29 2003-10-09 University Of Florida Lipid mediated screening of drug candidates for identification of active compounds
US20060094673A1 (en) * 2002-04-23 2006-05-04 Benjamin Chu Polymer surfactants for gene therapy applications
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
JP3415131B1 (ja) * 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040093198A1 (en) * 2002-11-08 2004-05-13 Carbon Design Systems Hardware simulation with access restrictions
MXPA05007348A (es) 2003-01-06 2005-10-05 Nektar Therapeutics Al Corp Derivados de polimeros solubles en agua tiol-selectivos.
EP1591450A4 (de) * 2003-01-10 2006-05-17 Yamanouchi Pharma Co Ltd Konjugat für retention im blut und krebsgewebespezifische wirkstofffreisetzung
WO2004078121A2 (en) * 2003-02-28 2004-09-16 Alza Coporation Liposome composition for reduction of liposome-induced complement activation
WO2004089339A2 (en) * 2003-03-31 2004-10-21 Alza Corporation Lipid particles having asymmetric lipid coating and method of preparing same
WO2004110493A2 (en) * 2003-05-30 2004-12-23 Alza Corporation Method of pulmonary administration of an agent
US8846079B1 (en) * 2004-12-01 2014-09-30 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US11324698B2 (en) 2003-08-28 2022-05-10 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
CA2560901C (en) * 2003-08-29 2012-08-21 The University Of Newcastle Research Associates Limited Stimulant sensitive flocculation and consolidation
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
AU2004283758A1 (en) * 2003-10-24 2005-05-06 Alza Corporation Preparation of lipid particles
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
JP2007520481A (ja) * 2004-01-15 2007-07-26 アルザ・コーポレーシヨン 治療薬を送達するためのリポソーム組成物
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
JP2008515929A (ja) * 2004-10-08 2008-05-15 アルザ コーポレイション 脂質連結部分を予備形成した脂質集合体にマイクロ波を使用して挿入する方法
WO2006088245A1 (ja) * 2005-02-18 2006-08-24 The University Of Tokushima ポリオキシアルキレン鎖含有脂質誘導体及び該誘導体を含有する脂質膜構造体
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2006127360A2 (en) * 2005-05-23 2006-11-30 Sdg, Inc. Lipid construct for delivery of interferon to a mammal
JP5329949B2 (ja) * 2005-05-31 2013-10-30 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
CA2896083A1 (en) 2005-12-08 2007-06-14 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
CA2654302A1 (en) 2006-06-05 2007-12-13 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
US20080031883A1 (en) * 2006-07-13 2008-02-07 Torchilin Vladimir P Condition-dependent, multiple target delivery system
US8343539B2 (en) * 2006-07-14 2013-01-01 Regents Of The University Of Minnesota Compounds that bind α5β1 integrin and methods of use
CA2658768C (en) 2006-07-21 2016-05-17 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
US20080213349A1 (en) * 2006-09-11 2008-09-04 Deepak Ramesh Thakker Liposome Complexes Containing Pharmaceutical Agents and Methods
EP2081548A2 (de) * 2006-09-22 2009-07-29 Labopharm Inc. Zusammensetzungen und verfahren für die ph-gezielte arzneiabgabe
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US20100210575A1 (en) * 2007-06-29 2010-08-19 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
US20110105995A1 (en) * 2008-01-16 2011-05-05 Zhu Ting F Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
WO2009154688A1 (en) * 2008-05-28 2009-12-23 President And Fellows Of Harvard College A pre-fabricated electron microscopy grid for monolayer purification and methods and kits therefor
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2310440A4 (de) * 2008-07-10 2013-06-05 Serina Therapeutics Inc Polyoxazoline mit inerten endgruppen, aus geschützten anfangsgruppen hergestellte polyoxazoline und entsprechende verbindungen
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
WO2010068432A1 (en) 2008-11-25 2010-06-17 Ecole Polytechnique Federale De Lausanne (Epfl) Block copolymers and uses thereof
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
EP2230515B1 (de) * 2009-03-16 2014-12-17 Agilent Technologies, Inc. Passivierung von Oberflächen nach Ligandenkupplung
NZ596186A (en) 2009-05-05 2014-03-28 Alnylam Pharmaceuticals Inc Lipid compositions
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011017297A2 (en) 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
DK2474306T3 (en) 2009-08-31 2017-02-06 Nanocarrier Co Ltd PARTICLE COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
AU2010326132B9 (en) 2009-12-01 2014-10-02 Translate Bio, Inc. Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
JP4829351B2 (ja) 2010-02-05 2011-12-07 ナノキャリア株式会社 易崩壊型ポリマーミセル組成物
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
KR101715981B1 (ko) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 뉴클레오사이드 포스포르아미데이트
WO2011123672A1 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate
RU2012151823A (ru) 2010-05-04 2014-06-10 Мерримак Фармасьютикалз, Инк. Антитела против рецептора эпидермального фактора роста (egfr) и их применение
WO2011160110A1 (en) 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
EP2609135A4 (de) 2010-08-26 2015-05-20 Massachusetts Inst Technology Poly(beta-amino-alkohole), ihre herstellung und verwendungen davon
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP3042910B1 (de) 2010-11-30 2019-01-09 Gilead Pharmasset LLC 2'-spiro-nukleoside zur therapie von hepatitis c
WO2012135025A2 (en) 2011-03-28 2012-10-04 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US10179106B2 (en) * 2011-05-12 2019-01-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Liposomes comprising polymer-conjugated lipids and related uses
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
CN111671918A (zh) 2011-06-08 2020-09-18 川斯勒佰尔公司 Mrna递送的脂质纳米颗粒组合物和方法
US8883989B2 (en) 2011-10-18 2014-11-11 Regents Of The University Of Minnesota Fractalkine binding polynucleotides and methods of use
EA032088B1 (ru) 2011-10-27 2019-04-30 Массачусетс Инститьют Оф Текнолоджи Аминокислотные производные, функционализованные на n-конце, способные образовывать микросферы, инкапсулирующие лекарственное средство
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
JP2015524410A (ja) 2012-07-18 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． エポキシケトン系プロテアソーム阻害剤のリポソーム組成物
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
CN102920658B (zh) * 2012-11-02 2015-01-21 艾韦特(溧阳)医药科技有限公司 与glp-1类似物和聚乙二醇结合的脂质体及其制备方法
RU2675859C2 (ru) 2012-11-29 2018-12-25 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
CN105188675A (zh) * 2013-03-13 2015-12-23 马林克罗特有限公司 经修饰多西他赛脂质体制剂
IL305374A (en) 2013-03-14 2023-10-01 Ethris Gmbh CFTR mRNA Assemblies and Related Methods and Uses
TR201901310T4 (tr) 2013-03-14 2019-02-21 Translate Bio Inc Mesajcı RNA'nın saflaştırılması yöntemleri.
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US10711106B2 (en) 2013-07-25 2020-07-14 The University Of Chicago High aspect ratio nanofibril materials
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
WO2015061491A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
SG11201602943PA (en) 2013-10-22 2016-05-30 Shire Human Genetic Therapies Lipid formulations for delivery of messenger rna
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
RU2020104969A (ru) 2014-01-31 2020-03-13 Фэктор Байосайенс Инк. Способы и продукты для получения и доставки нуклеиновых кислот
US10869898B2 (en) 2014-04-01 2020-12-22 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
CN106164248B (zh) 2014-04-25 2019-10-15 川斯勒佰尔公司 信使rna的纯化方法
ES2926985T3 (es) 2014-05-15 2022-10-31 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas
US10022455B2 (en) 2014-05-30 2018-07-17 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
KR102511554B1 (ko) 2014-06-24 2023-03-16 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
EP3164379A1 (de) 2014-07-02 2017-05-10 Massachusetts Institute of Technology Lipidoide aus polyaminfettsäure und verwendungen davon
CN104546722B (zh) * 2015-02-10 2017-05-24 中国医学科学院医药生物技术研究所 米铂脂质体和制法
JP7199809B2 (ja) 2015-02-13 2023-01-06 ファクター バイオサイエンス インコーポレイテッド 核酸製品及びその投与方法
CN107848988B (zh) 2015-06-19 2021-10-22 麻省理工学院 烯基取代的2,5-哌嗪二酮和其在组合物中用于向个体或细胞递送药剂的用途
CA2990247C (en) * 2015-07-09 2023-10-03 The Regents Of The University Of California Fusogenic liposome-coated porous silicon nanoparticles
US10517823B1 (en) * 2016-08-10 2019-12-31 Verily Life Sciences Llc ROS—responsive liposomes for specific targeting
US10583083B1 (en) 2016-08-10 2020-03-10 Verily Life Sciences Llc ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA
CA3056797A1 (en) 2017-03-16 2018-09-20 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
CA3060442A1 (en) * 2017-04-19 2018-10-25 Apa- Advanced Technologies Ltd. Fusogenic liposomes, compositions, kits and use thereof for treating cancer
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3700965A1 (de) 2017-10-27 2020-09-02 Massachusetts Institute of Technology Poly(beta-aminoester) und deren verwendungen
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
WO2020084623A2 (en) * 2018-10-24 2020-04-30 Apa- Advanced Technologies Ltd. Fusogenic liposomes for selective imaging of tumor cells
US11608412B2 (en) 2018-10-26 2023-03-21 Massachusetts Institute Of Technology Polymer-lipids and compositions
WO2023210671A1 (ja) * 2022-04-26 2023-11-02 京セラ株式会社 共重合体、高分子膜、測定用装置および測定用担体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136095A (en) * 1987-05-19 1992-08-04 Syntex (U.S.A.) Inc. Reversible agglutination mediators
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JPH07173079A (ja) * 1992-12-22 1995-07-11 Nippon Oil & Fats Co Ltd 両親媒性ポリエチレングリコール誘導体および用途
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes

Also Published As

Publication number Publication date
IL129292A0 (en) 2000-02-17
CA2267904A1 (en) 1998-04-23
TW520297B (en) 2003-02-11
JP2001504093A (ja) 2001-03-27
AU715063B2 (en) 2000-01-13
DK0932391T3 (da) 2003-05-26
US5891468A (en) 1999-04-06
HK1047550A1 (zh) 2003-02-28
EP0932391A2 (de) 1999-08-04
BR9712230A (pt) 2000-01-25
DE69718924T2 (de) 2003-12-04
PT932391E (pt) 2003-06-30
WO1998016202A2 (en) 1998-04-23
EP0932391B1 (de) 2003-02-05
ATE232086T1 (de) 2003-02-15
CA2267904C (en) 2005-08-02
WO1998016202A3 (en) 1998-07-16
AU4987897A (en) 1998-05-11
ES2191833T3 (es) 2003-09-16

Similar Documents

Publication Publication Date Title
DE69718924T2 (de) Fusogene liposomzusammensetzung und verfahren
MY122195A (en) New controlled release bead, a method of producing the same and multiple unit formulation comprising it
IL142573A0 (en) Liposome-entrapped topoisomerase inhibitors
DE69725747D1 (de) Liposome enthaltend cisplatin
DK0924784T3 (da) CO-ufølsom anodekatalysator til brændselsceller med polymerelektrolyt-membraner samt fremgangsmåde til fremstilling deraf
ES555277A0 (es) Procedimiento de obtencion de una composicion de injerto para la liberacion controlada de macromoleculas
AU1742597A (en) A hydrophilic, graphite fuel cell electrode for use with an ionomer membrane and method of making a fuel cell
MXPA02004574A (es) Formulacion farmaceutica que contiene tolterodina y su uso.
DE69710787D1 (de) Komposit-kathoden, elektrochemische zellen mit komposit-kathoden und verfahren zur herstellung
AU1406897A (en) New polymer material for electrolytic membranes in fuel cells
EP0875524A3 (de) Verbundmembranen
DE69834177D1 (de) Biozides puder mit verzögerter freisetzung
AU6266398A (en) Method of preparing electrochemical cells
DE69838244D1 (de) Sekundärzelle mit nichtwässrigem elektrolyten und verfahren zur herstellung positiver aktiver materialien dafür
DE69706592D1 (de) Verfahren zur Herstellung von positivelektrode-aktivem Material, sowie diese verwendende nichtwässerige Sekundärbatterie
AU2124495A (en) Bipolar battery cells, batteries, and methods
AU6354196A (en) A wound electrochemical cell, a method for the manufacture thereof, and the use of such electrochemical cells
AU7277598A (en) Energy delivery of catheter and method for the use thereof
EP1214935A3 (de) Fusogene Liposomenzusammensetzung und Verfahren
AU673414B2 (en) Cathodic active material composition for dry cells, method for preparing the same, and alkaline battery
AU2275697A (en) Use of cell membrane permeants in the treatment of cellular proliferative disea ses
WO2001013446A2 (fr) Materiau pour electrode positive de pile secondaire au lithium et son procede de preparation
AU7489996A (en) A negative electrode composition for lithium secondary batteries, a method for the production thereof, use of said composition in lithium secondary batteries and lithium secondary batteries containing said negative electrode composition
WO1998052613A3 (en) Method of administration for a therapeutic agent utilizing suitable forms of hyaluronic acid and combinations with electroporation
AU6130299A (en) Use of mcrp for delivery of materials into cells

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee